Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207532 | 0.88 | PPARA (0.52) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL1417534 | 0.88 | FBP1 (0.62) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL3904657 | 0.87 | FBP1 (0.52) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL12860025 | 0.86 | FBP1 (0.51) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL2824290 | 0.86 | PPARA (0.61) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL3905611 | 0.85 | PPARA (0.52) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL5476491 | 0.83 | FBP1 (0.53) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL7974421 | 0.83 | FBP1 (0.50) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL21188249 | 0.82 | FBP1 (0.51) | FBP1PPARACYP1A2ABCB11CYP3A4 | |
| SCHEMBL9034864 | 0.82 | PPARA (0.49) | FBP1PPARACYP1A2ABCB11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | PPARD, PPARA, PPARG | FBP1 1668/4885PPARA 2/4885CYP1A2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.